



Susan Knox, MD, PhD

Associate Professor of Radiation Oncology
Radiation Oncology - Radiation Therapy

CLINICAL OFFICES

- **Radiation Therapy**

875 Blake Wilbur Dr Clinic D

Stanford, CA 94305

Tel (650) 723-6171

Fax (650) 725-8231

Bio

BIO

Dr. Susan Knox specializes in the treatment of breast cancer and melanoma, and sees a variety of general radiation oncology patients. She has practiced as a radiation oncologist for more than 25 years.

A primary area of research in Dr. Knox's laboratory is the study of novel therapies (targeted therapies, radiosensitizers, radioprotectors, and biological response modifiers) for the treatment of solid tumors, with a particular focus on prostate cancer, breast cancer and melanoma, using small animal tumor models. Her research is interdisciplinary and spans the study of mechanisms of action at the molecular level to translational studies and early clinical trials. Her drug discovery/development work, and research on innovative therapeutic approaches has resulted in 3 new ongoing clinical trials. A major focus of both her laboratory and clinical research is the use of radiation as a component of in situ tumor vaccine strategies. She has had a long-standing interest in clinical research and has served as a PI on numerous clinical trials and as a member of the Clinical Oncology Study Section. As the Faculty Director of the PRMS for the Stanford Cancer Institute, she oversees the Scientific Review Committee and chairs the Data and Safety Monitoring Committee.

CLINICAL FOCUS

- Cancer > Cutaneous (Dermatologic) Oncology
- Cancer > Lymphoma
- Cancer > Radiation Oncology
- Radiation Oncology
- Radiation Therapy
- Lymphoma, Transplantation, Breast Cancer, Targeted Therapies

ACADEMIC APPOINTMENTS

- Associate Professor, Radiation Oncology - Radiation Therapy
- Member, Bio-X
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Program Evaluation Committee Member, Department of Radiation Oncology, (2014- present)
- Working Group Member, Society of Nuclear Medicine and Molecular Imaging, (2014- present)
- Committee Member, Stanford University on Health and Safety, (2013-2016)
- Executive Committee Member: Cancer Clinical Trials Office, Stanford Cancer Center, (2011- present)
- Executive Committee Member: Clinical Research Oversight Group, Stanford Cancer Center, (2011- present)
- Department Representative, School of Medicine Faculty Senate, (2011-2016)
- Committee Member, SAMFUND Selection Committee, (2010- present)
- Committee Member, SPARK Committee, (2009- present)
- BioX Program Member, Stanford University, (2008- present)
- Lymphoma Disease Management Group Member, Stanford Cancer Center, (2008- present)
- The Molecular Therapeutics Program, Stanford Cancer Center, (2008- present)
- Committee Member, Committee on Professionalism, Performance and Promotion, (2007- present)
- Committee on the State of Science in Nuclear Medicine, Subcommittee on Targeted Radiotherapy, The National Academies, (2006- present)
- Advisory Board and Training Committee, NIH T32 SCIT CA09695, (2005- present)
- Medical Education Leadership Group, Stanford Cancer Center, (2005- present)
- President, Alumni Association, Stanford School of Medicine, (2005-2007)
- Director, Core: Protocol Review and Monitoring System, Stanford Cancer Center, (2004- present)
- Chair, Data and Safety Monitoring Committee, Stanford Clinical Trials Office, Cancer Center, (2003- present)
- Executive Committee, Clinical Cancer Center, (2003- present)
- Associate Editor, Journal of Clinical Oncology, (2003-2006)
- Assistant Dean for Medical Student Advising, Stanford University School of Medicine, (2002- present)
- Member, Clinical Oncology Study Section, (2001-2004)
- Board of Governors, Stanford Medical Alumni Association, (2000-2007)
- Associate Editor, Radiation Research, (2000-2003)
- Editorial Board Member, Cancer Biotherapy and Radiopharmaceuticals, (1996- present)

HONORS AND AWARDS

- President, Alumni Association, Stanford University School of Medicine (2005-2007)
- Elected Councilor Medicine, Radiation Research Society (2003)
- Charles F. Kettering Selection Committee, General Motors Cancer Research Foundation (2000-2002)
- Board of Governors, Stanford Medical Alumni Association (2000-2008)
- Lazard Faculty Scholar, Lazard Faculty (1992-93)
- Clinical Oncology Career Development Award, American Cancer Society (1991-94)
- Leadership in Education, Stanford University School of Medicine (2008)

PROFESSIONAL EDUCATION

- Residency: Stanford University School of Medicine Registrar (1990) CA
- Fellowship: Stanford University School of Medicine Registrar (1989) CA
- Internship: UC Davis Medical Center (1986) CA

- Medical Education: Stanford University School of Medicine (1985) CA
- Post Doc Fellow, Stanford Univ. Hospital , Medical Oncology (1989)
- Medical Intern, UC Davis, California (1986)
- Post-Doc Fellow/Res. Assist., Stanford Univ. Hospital , Medical Oncology (1989)
- MD, Stanford University (1985)
- Post-Doc Res. Immunologist, UC Davis, California , Energy-Related Health Research
- PhD, UC Davis, California (1980)
- AB, UC Berkeley, California, (1974)

LINKS

- <http://www.stanford.edu/group/RIT>: <http://www.stanford.edu/group/RIT>
- Personal Web site / Radiation Oncology (Dept) Web site: <http://www.stanford.edu/group/RIT>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

- Radioimmunotherapy (RIT) and Systemically Targeted Radiation Therapy
- Low Dose Rate Effects
- Radioprotective Agents, Growth Factors/Receptors
- Oncogenes, Apoptosis & Radiosensitivity
- Apoptosis and Signal Transduction Pathways
- Effects of Radiation on the Immune Response
- Biological Response Modifiers and Novel Targeted Radiosensitizers
- Non-Hodgkin's Lymphomas
- Mycosis Fungoides
- Breast and Prostate Cancer
- Radiation as a component of Tumor Vaccine Strategies

CLINICAL TRIALS

- A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma, Not Recruiting
- CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas, Not Recruiting
- Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy, Not Recruiting
- Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy, Not Recruiting
- Phase 2 Study of Bexxar in Relapsed/Refractory DLCL, Not Recruiting
- Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer, Not Recruiting
- Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma, Not Recruiting
- Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy, Not Recruiting
- Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer, Not Recruiting
- Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy, Not Recruiting

Teaching

STANFORD ADVISEES

Academic Advising Dean

Winston Becker, Thomas Chew, Michelle Drews, Kyle Eagen, Cordelia Erickson-Davis, Ryan Flynn, Michelle Han, Joy He, Mark Jeng, Lori Lee, Michelle Nguyen, Nancy Nkansah-Mahaney, Justin Norden, Jaspreet Pannu, John Pluvinage, Tyler Prestwood, Julia Ransohoff, Anirudh Saraswathula, Zahra Sayyid, Gerald Tiu

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Cancer Biology (Phd Program)
- Immunology (Phd Program)
- Molecular and Genetic Medicine (Fellowship Program)

Publications

PUBLICATIONS

- **A note on improved statistical approaches to account for pseudoprogression** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Abrouk, N., Oronsky, B., Caroen, S., Ning, S., Knox, S., Peehl, D.
2018; 81 (3): 621–26
- **The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry** *CLINICAL EPIGENETICS*
Zhao, H., Ning, S., Nolley, R., Scicinski, J., Oronsky, B., Knox, S. J., Peehl, D. M.
2017; 9
- **RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials** *EXPERT OPINION ON INVESTIGATIONAL DRUGS*
Oronsky, B., Paulmurugan, R., Foygel, K., Scicinski, J., Knox, S. J., Peehl, D., Zhao, H., Ning, S., Cabrales, P., Summers, T. A., Reid, T. R., Fitch, W. L., Kim, et al
2017; 26 (1): 109-119
- **Phase I Trial: SABR and Ipilimumab-Letter.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Hiniker, S. M., Reddy, S. A., Swetter, S. M., Knox, S. J.
2017; 23 (1): 320
- **A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma.** *International journal of radiation oncology, biology, physics*
Hiniker, S. M., Reddy, S. A., Maecker, H. T., Subrahmanyam, P. B., Rosenberg-Hasson, Y., Swetter, S. M., Saha, S., Shura, L., Knox, S. J.
2016; 96 (3): 578-588
- **RRx-001, A novel dinitroazetidine radiosensitizer** *INVESTIGATIONAL NEW DRUGS*
Oronsky, B., Scicinski, J., Ning, S., Peehl, D., Oronsky, A., Cabrales, P., Bednarski, M., Knox, S.
2016; 34 (3): 371-377
- **Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial.** *Translational oncology*
Kim, M. M., Parmar, H., Cao, Y., Pramanik, P., Schipper, M., Hayman, J., Junck, L., Mammoser, A., Heth, J., Carter, C. A., Oronsky, A., Knox, S. J., Caroen, et al
2016; 9 (2): 108-113
- **Rockets, Radiosensitizers, and RRx-001: An Origin Story Part I** *DISCOVERY MEDICINE*
Oronsky, B., Scicinski, J., Ning, S., Peehl, D., Oronsky, A., Cabrales, P., Bednarski, M., Knox, S.
2016; 115: 173-180
- **Rockets, radiosensitizers, and RRx-001: an origin story part I.** *Discovery medicine*
Oronsky, B., Scicinski, J., Ning, S., Peehl, D., Oronsky, A., Cabrales, P., Bednarski, M., Knox, S.
2016; 21 (115): 173-180

- **Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity.** *Oncotarget*
Zhao, H., Ning, S., Scicinski, J., Oronsky, B., Knox, S. J., Peehl, D. M.
2015; 6 (41): 43172-43181
- **NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001** *REDOX BIOLOGY*
Scicinski, J., Oronsky, B., Ning, S., Knox, S., Peehl, D., Kim, M. M., Langecker, P., Fanger, G.
2015; 6: 1-8
- **Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study** *LANCET ONCOLOGY*
Reid, T., Oronsky, B., Scicinski, J., Scribner, C. L., Knox, S. J., Ning, S., Peehl, D. M., Korn, R., Stirn, M., Carter, C. A., Oronsky, A., Taylor, M. J., Fitch, et al
2015; 16 (9): 1133-1142
- **Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001.** *Oncotarget*
Ning, S., Sekar, T. V., Scicinski, J., Oronsky, B., Peehl, D. M., Knox, S. J., Paulmurugan, R.
2015; 6 (25): 21547-21556
- **The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.** *Redox biology*
Scicinski, J., Fisher, G., Carter, C., Cho-Phan, C., Kunz, P., Ning, S., Knox, S., Oronsky, B., Caroen, S., Parker, C., Fanger, G., Reid, T.
2015; 5: 422-?
- **Predictors of clinical response to immunotherapy with or without radiotherapy.** *Journal of radiation oncology*
Hiniker, S. M., Maecker, H. T., Knox, S. J.
2015; 4: 339-345
- **Immunotherapy and radiation.** *Seminars in oncology*
Hiniker, S. M., Knox, S. J.
2014; 41 (6): 702-713
- **Novel Human Radiation Exposure Biomarker Panel Applicable for Population Triage** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Bazan, J. G., Chang, P., Balog, R., D'Andrea, A., Shaler, T., Lin, H., Lee, S., Harrison, T., Shura, L., Schoen, L., Knox, S. J., Cooper, D. E.
2014; 90 (3): 612-619
- **The Implications of Hyponitroxia in Cancer** *TRANSLATIONAL ONCOLOGY*
Oronsky, B., Fanger, G. R., Oronsky, N., Knox, S., Scicinski, J.
2014; 7 (2): 167-173
- **The implications of hyponitroxia in cancer** *Translational Oncology*
Oronsky, B., Fanger, G., Oronsky, N., Knox, S. J., Scicinski, J.
2014; 7 (2): 167-173
- **Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients.** *Case reports in oncology*
Reid, T., Dad, S., Korn, R., Oronsky, B., Knox, S., Scicinski, J.
2014; 7 (1): 79-85
- **Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment** *ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY*
Oronsky, B., Oronsky, N., Knox, S., Fanger, G., Scicinski, J.
2014; 14 (8): 1121-1127
- **Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy** *Biochemical and Biophysical Research Communications*
Ning, S., Bednarski, M., Oronsky, B., Scicinski, J., Knox, S. J.
2014; 447 (3): 537-542
- **Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients** *Case Reports in Oncology*
Reid, T., Dad, S., Korn, R., Oronsky, G., Knox, S. J., Scicinski, J.
2014; 7 (1): 79-85

- **Topical hypochlorite ameliorates NF-kappa B-mediated skin diseases in mice** *JOURNAL OF CLINICAL INVESTIGATION*
Leung, T. H., Zhang, L. F., Wang, J., Ning, S., Knox, S. J., Kim, S. K.
2013; 123 (12): 5361-5370
- **Radioprotection and Cell Cycle Arrest of Intestinal Epithelial Cells by Darinaparsin, a Tumor Radiosensitizer** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Tian, J., Doi, H., Saar, M., Santos, J., Li, X., Peehl, D. M., Knox, S. J.
2013; 87 (5): 1179-1185
- **Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line** *CLINICAL IMMUNOLOGY*
Parker, J. J., Jones, J. C., Strober, S., Knox, S. J.
2013; 148 (1): 44-55
- **Phase I Study of a Modified Regimen of (90)Yttrium-Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+Non-Hodgkin Lymphoma** *CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS*
Vaklavas, C., Meredith, R. F., Shen, S., Knox, S. J., Micallef, I. N., Shah, J. J., LoBuglio, A. F., Forero-Torres, A.
2013; 28 (5): 370-379
- **Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm.** *Theranostics*
Paulmurugan, R., Oronsky, B., Brouse, C. F., Reid, T., Knox, S., Scicinski, J.
2013; 3 (6): 437-447
- **Topical hypochlorite ameliorates NF-kB-mediated skin diseases in mice** *The Journal of Clinical Investigation*
Leung, T. H., Zhang, L. F., Wang, J., Ning, S., Knox, S. K., Kim, S. K.
2013; 123 (12): 5361-5370
- **A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy** *TRANSLATIONAL ONCOLOGY*
Hiniker, S. M., Chen, D. S., Reddy, S., Chang, D. T., Jones, J. C., Mollick, J. A., Swetter, S. M., Knox, S. J.
2012; 5 (6): 404-407
- **The Scarlet Letter of Alkylation: A Mini Review of Selective Alkylating Agents** *TRANSLATIONAL ONCOLOGY*
Oronsky, B. T., Reid, T., Knox, S. J., Scicinski, J. J.
2012; 5 (4): 226-229
- **Mitigation of Radiation-Induced Dermatitis by Activation of Aldehyde Dehydrogenase 2 Using Topical Alda-1 in Mice** *RADIATION RESEARCH*
Ning, S., Budas, G. R., Churchill, E. N., Chen, C., Knox, S. J., Mochly-Rosen, D.
2012; 178 (1): 69-74
- **Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer** *CLINICAL CANCER RESEARCH*
Tian, J., Zhao, H., Nolley, R., Reese, S. W., Young, S. R., Li, X., Peehl, D. M., Knox, S. J.
2012; 18 (12): 3366-3376
- **Beyond Antiangiogenesis: Vascular Modulation as an Anticancer Therapy-A Review** *TRANSLATIONAL ONCOLOGY*
Oronsky, B. T., Scicinski, J. J., Reid, T., Knox, S.
2012; 5 (3): 133-140
- **Abscopal Effect in a Patient with Melanoma** *NEW ENGLAND JOURNAL OF MEDICINE*
Hiniker, S. M., Chen, D. S., Knox, S. J.
2012; 366 (21): 2035-2035
- **Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials** *CANCER RESEARCH*
Ning, S., Bednarski, M., Oronsky, B., Scicinski, J., Saul, G., Knox, S. J.
2012; 72 (10): 2600-2608
- **Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review** *TRANSLATIONAL ONCOLOGY*
Oronsky, B. T., Knox, S. J., Scicinski, J. J.
2012; 5 (2): 66-71

- **Six degrees of separation: the oxygen effect in the development of radiosensitizers.** *Translational oncology*
Oronsky, B. T., Knox, S. J., Scicinski, J.
2011; 4 (4): 189-198
- **Anti-tumor and radiosensitization activities of the iron chelator HDP44mT are mediated by effects on intracellular redox status** *CANCER LETTERS*
Tian, J., Peehl, D. M., Zheng, W., Knox, S. J.
2010; 298 (2): 231-237
- **In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study** *JOURNAL OF CLINICAL ONCOLOGY*
Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., Kim, Y. H., Hoppe, R. T., Knox, S. J., Shin, L. K., Wapnir, I., Tibshirani, R. J., Levy, et al
2010; 28 (28): 4324-4332
- **Anti-alpha v Integrin Monoclonal Antibody Intetumumab Enhances the Efficacy of Radiation Therapy and Reduces Metastasis of Human Cancer Xenografts in Nude Rats** *CANCER RESEARCH*
Ning, S., Tian, J., Marshall, D. J., Knox, S. J.
2010; 70 (19): 7591-7599
- **SODIUM SELENITE RADIOSENSITIZES HORMONE-REFRACTORY PROSTATE CANCER XENOGRAFT TUMORS BUT NOT INTESTINAL CRYPT CELLS IN VIVO** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Tian, J., Ning, S., Knox, S. J.
2010; 78 (1): 230-236
- **Metalloporphyrin Synergizes with Ascorbic Acid to Inhibit Cancer Cell Growth Through Fenton Chemistry** *CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS*
Tian, J., Peehl, D. M., Knox, S. J.
2010; 25 (4): 439-448
- **I-131-Tositumomab (Bexxar (R)) vs. Y-90-Ibritumomab (Zevalin (R)) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma** *MOLECULAR IMAGING AND BIOLOGY*
Iagaru, A., Mitra, E. S., Ganjoo, K., Knox, S. J., Goris, M. L.
2010; 12 (2): 198-203
- **Impact of Rituximab Treatment on Y-90-Ibritumomab Dosimetry for Patients with Non-Hodgkin Lymphoma** *JOURNAL OF NUCLEAR MEDICINE*
Shen, S., Forero, A., Meredith, R. F., Shah, J. J., Knox, S. J., Wiseman, G. A., Usrey, M. E., LoBuglio, A. F.
2010; 51 (1): 150-157
- **Impact of Radiation on Immunotherapy Targets** *24th Annual Meeting of the International-Society-for-Biology-Therapy-of-Cancer*
Jones, J. C., Knox, S. J.
LIPPINCOTT WILLIAMS & WILKINS.2009: 971-72
- **Lanreotide promotes apoptosis and is not radioprotective in GH3 cells** *ENDOCRINE-RELATED CANCER*
Ning, S., Knox, S. J., Harsh, G. R., Culler, M. D., Katznelson, L.
2009; 16 (3): 1045-1055
- **Identification of Novel Radiation Induced Immune Signaling Changes in Antigen Presenting Cells** *51st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO)*
Parker, J. J., Jones, J. C., Strober, S., Knox, S.
ELSEVIER SCIENCE INC.2009: S545-S545
- **Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Bhattacharyya, R. S., Husbeck, B., Feldman, D., Knox, S. J.
2008; 72 (3): 935-940
- **Risks to normal tissues from radionuclide therapy** *SEMINARS IN NUCLEAR MEDICINE*
Meredith, R., Wessels, B., Knox, S.
2008; 38 (5): 347-357
- **Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo** *MOLECULAR CANCER THERAPEUTICS*

- Ning, S., Nemeth, J. A., Hanson, R. L., Forsythe, K., Knox, S. J.
2008; 7 (6): 1569-1578
- **CNTO 95, a monoclonal antibody against alpha v integrins, enhances the therapeutic efficacy of fractionated radiation therapy in vivo.**
Ning, S., Nemeth, J. A., Hanson, R. L., Forsythe, K., Knox, S. J.
AMER ASSOC CANCER RESEARCH.2007: 3537S-3537S
 - **MIRD continuing education: Bystander and low-dose-rate effects: Are these relevant to Radionuclide therapy? *JOURNAL OF NUCLEAR MEDICINE***
Sgouros, G., Knox, S. J., Joiner, M. C., Morgan, W. F., Kassis, A. I.
2007; 48 (10): 1683-1691
 - **Expression and function of erythropoietin receptors in tumors - Implications for the use of erythropoiesis-stimulating agents in cancer patients *CANCER***
Sinclair, A. M., Todd, M. D., Forsythe, K., Knox, S. J., Elliott, S., Begley, C. G.
2007; 110 (3): 477-488
 - **Targeting integrins and PI3K/Akt-mediated signal transduction pathways enhances radiation-induced anti-angiogenesis *RADIATION RESEARCH***
Ning, S., Chen, Z., Dirks, A., Husbeck, B., Hsu, M., Bedogni, B., O'Neill, M., Powell, M. B., Knox, S. J.
2007; 168 (1): 125-133
 - **Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma *BLOOD***
Kim, Y. H., Duvic, M., Obitz, E., Gniadecki, R., Iversen, L., Osterborg, A., Whittaker, S., Illidge, T. M., Schwarz, T., Kaufmann, R., Cooper, K., Knudsen, K. M., Lisby, et al
2007; 109 (11): 4655-4662
 - **Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action *MOLECULAR CANCER THERAPEUTICS***
Husbeck, B., Bhattacharyya, R. S., Feldman, D., Knox, S. J.
2006; 5 (8): 2078-2085
 - **Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS***
Ning, S., Knox, S. J.
2006; 65 (2): 493-498
 - **Phase I study of I-131-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer *CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS***
Street, H. H., Goris, M. L., Fisher, G. A., Wessels, B. W., Cho, C., Hernandez, C., Zhu, H. J., Zhang, Y., Nangiana, J. S., Shan, J. S., Roberts, K., Knox, S. J.
2006; 21 (3): 243-256
 - **Radiation sensitization with redox modulators: A promising approach *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS***
Rosenberg, A., Knox, S.
2006; 64 (2): 343-354
 - **Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells *PROSTATE***
Husbeck, B., Nonn, L., Peehl, D. M., Knox, S. J.
2006; 66 (2): 218-225
 - **Clinical manifestations of noncoronary atherosclerotic vascular disease after moderate dose irradiation *CANCER***
Patel, D. A., Kochanski, J., Suen, A. W., Fajardo, L. F., Hancock, S. L., Knox, S. J.
2006; 106 (3): 718-725
 - **Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma *Systemics Targeted Radionuclide Therapy Symposium (STaRT)***
Meredith, R. F., Knox, S. J.
ELSEVIER SCIENCE INC.2006: S15-S22
 - **A preliminary report of a phase I study of Zevalin (R) using a modified treatment regimen for relapsed or refractory CD20+B-cell follicular or transformed non-Hodgkin's lymphoma (NHL) *47th Annual Meeting of the American-Society-of-Hematology***
Forero-Torres, A., Shah, J., Besh, S., Knox, S., Micallef, I., Wiseman, G., Witzig, T., Lobuglio, A., Shen, S., Goris, M., Connor, J., Meredith, R.
AMER SOC HEMATOLOGY.2005: 280B-280B

- **Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab** *45th Annual Meeting and Exhibition of the American-Society-of-Hematology*
Kaminski, M. S., Radford, J. A., Gregory, S. A., Leonard, J. P., Knox, S. J., KROLL, S., Wahl, R. L.
AMER SOC CLINICAL ONCOLOGY.2005: 7985-93
- **Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas** *JOURNAL OF CLINICAL ONCOLOGY*
Fisher, R. I., Kaminski, M. S., Wahl, R. L., Knox, S. J., Zelenetz, A. D., Vose, J. M., Leonard, J. P., KROLL, S., Goldsmith, S. J., Coleman, M.
2005; 23 (30): 7565-7573
- **Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I-131 tositumomab** *BLOOD*
Bennett, J. M., Kaminski, M. S., Leonard, J. P., Vose, J. M., Zelenetz, A. D., Knox, S. J., Horning, S., Press, O. W., Radford, J. A., Kroll, S. M., Capizzi, R. L.
2005; 105 (12): 4576-4582
- **Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing** *FREE RADICAL BIOLOGY AND MEDICINE*
Husbeck, B., Peehl, D. M., Knox, S. J.
2005; 38 (1): 50-57
- **Darbepoietin alfa potentiates the efficacy of radiation therapy in mice with corrected or uncorrected anemia** *CANCER RESEARCH*
Ning, S. C., Hartley, C., Molineux, G., Knox, S. J.
2005; 65 (1): 284-290
- **The radioisotope contributes significantly to the activity of radioimmunotherapy** *CLINICAL CANCER RESEARCH*
Davis, T. A., Kaminski, M. S., Leonard, J. P., Hsu, F. J., Wilkinson, M., Zelenetz, A., Wahl, R. L., KROLL, S., Coleman, M., Goris, M., Levy, R., Knox, S. J.
2004; 10 (23): 7792-7798
- **Enhancement of the efficacy of an antagonist of an extracellular receptor by attachment to the surface of a biocompatible carrier** *PHARMACEUTICAL RESEARCH*
Wartchow, C. A., Alters, S. E., Garzone, P. D., Li, L. Y., Choi, S., DeChene, N. E., Doede, T., Huang, L., Pease, J. S., Shen, Z. M., Knox, S. J., Cleland, J. L.
2004; 21 (10): 1880-1885
- **Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Ning, S. C., Knox, S. J.
2004; 60 (1): 197-203
- **Enhanced effectiveness of radiochemotherapy with tirapazamine by local application of electric pulses to tumors** *RADIATION RESEARCH*
Maxim, P. G., Carson, J. J., Ning, S. C., Knox, S. J., Boyer, A. L., Hsu, C. P., Benaron, D. A., Walleczek, J.
2004; 162 (2): 185-193
- **Phase I study of I-131-chimeric(ch) TNT-1/B antibody for the treatment of advanced colorectal cancer** *10th Conference on Cancer Therapy with Antibodies and Immunoconjugates*
Knox, S., Fisher, G., Wessels, B., Cho, C., Hernandez, M. C., Street, H., Nangiana, J., Shan, J., Goris, M.
MARY ANN LIEBERT INC.2004: 528-28
- **Radiobiology of radioimmunotherapy: Targeting CD20 B-cell antigen in non-Hodgkin's lymphoma** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Hernandez, M. C., Knox, S. J.
2004; 59 (5): 1274-1287
- **Phase I trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma** *BLOOD*
Forero, A., Weiden, P. L., Vose, J. M., Knox, S. J., LoBuglio, A. F., Hankins, J., Goris, M. L., Picozzi, V. J., Axworthy, D. B., Breitz, H. B., Sims, R. B., Ghalie, R. G., Shen, et al
2004; 104 (1): 227-236
- **Dosimetry model for radioactivity localized to intestinal mucosa** *CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS*
Fisher, D., Rajon, D., Breitz, H., Goris, M., Bolch, W., Knox, S.
2004; 19 (3): 293-307

- **A novel antiangiogenesis therapy using an integrin antagonist or anti-FLK-1 antibody coated Y-90-labeled nanoparticles** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Li, L. Y., Wartchow, C. A., Danthi, S. N., Shen, Z. M., DeChene, N., PEASE, J., Choi, H. S., Doede, T., Chu, P., Ning, S. C., Lee, D. Y., Bednarski, M. D., Knox, et al
2004; 58 (4): 1215-1227
- **HuMax-CD4, fully human monoclonal antibody: Phase II trial in cutaneous T cell lymphoma** *65th Annual Meeting of the Society-for-Investigative-Dermatology*
Kim, Y. H., Obitz, E., Iversen, L., Oesterborg, A., Whittaker, S., Illidge, T. M., Schwarz, T., Kaufmann, R., Gniadecki, R., Duvic, M., Cooper, K., Jensen, P., Baadsgaard, et al
NATURE PUBLISHING GROUP.2004: A57-A57
- **Radiation-induced cyclooxygenase 2 up-regulation is dependent on redox status in prostate cancer cells** *RADIATION RESEARCH*
Li, L. Y., Steinauer, K. K., Dirks, A. J., Husbeck, B., Gibbs, I., Knox, S. J.
2003; 160 (6): 617-621
- **Radiobiology of radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin)** *SEMINARS IN ONCOLOGY*
Hernandez, M. C., Knox, S. J.
2003; 30 (6): 6-10
- **Higher doses of Rituxan (R) alter pharmacokinetics and biodistribution of Zevalin (R) but may increase responses; a preliminary report of a phase I study of Zevalin (R) using a modified treatment regimen for relapsed or refractory CD20+B-cell follicular/transformed non-Hodgkin's lymphoma.** *45th Annual Meeting and Exhibition of the American-Society-of-Hematology*
Forero-Torres, A., Besh, S., Knox, S., Micallef, I., Wiseman, G., Witzig, T., Lobuglio, A., Shen, S., Goris, M., CARPENTER, M., Meredith, R.
AMER SOC HEMATOLOGY.2003: 408A-408A
- **Long-term results of a randomized trial comparing Tositumomab and Iodine-131 Tositumomab (BEXXAR (R)) with Tositumomab alone in patients with relapsed or refractory low-grade (LG) or transformed low grade (T-LG) Non-Hodgkin's Lymphoma (NHL).** *45th Annual Meeting and Exhibition of the American-Society-of-Hematology*
Davis, T., Kaminski, M. S., Leonard, J. P., Hsu, F. J., Wilkinson, M., Wahl, R., Coleman, M., Goris, M., Levy, R., Knox, S.
AMER SOC HEMATOLOGY.2003: 405A-406A
- **Cell surface receptor-targeted dextran-coated liposomes for the treatment of solid tumors.** *226th National Meeting of the American-Chemical-Society*
Wartchow, C. A., Alters, S. E., Choi, S., DeChene, N. E., Doede, T., Huang, L. N., Pease, J. S., Shen, Z. M., Li, L. Y., Cleland, J. L., Knox, S. J.
AMER CHEMICAL SOC.2003: U468-U468
- **Distribution of monoclonal antiferritin antibody in Kaposi's sarcoma, Hodgkin's disease, and hepatocellular carcinoma** *HUMAN PATHOLOGY*
Yuen, A. R., Higgins, J. P., Baker, R., Kamel, O. W., Warnke, R. A., Knox, S. J.
2003; 34 (4): 381-384
- **Pretarget radioimmunotherapy (RIT) with anti-CD20 fusion protein in patients with non-Hodgkin's lymphoma (NHL).**
Meredith, R., Shen, S., Breitz, H., Fisher, D., Goris, M., Knox, S., Hankins, J., Vose, J., Picozzi, V.
SOC NUCLEAR MEDICINE INC.2002: 116P-117P
- **Synthesis of multivalent nanoparticles for use in targeting vascular receptors.**
Danthi, S. N., Li, L. Y., Ning, S. C., Choi, H. S., Wartchow, C. A., Lee, D., Knox, S. J., Bednarski, M. D.
AMER CHEMICAL SOC.2002: A109-A109
- **Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line** *CELL DEATH AND DIFFERENTIATION*
Armstrong, J. S., Steinauer, K. K., Hornung, B., Irish, J. M., Lecane, P., Birrell, G. W., Peehl, D. M., Knox, S. J.
2002; 9 (3): 252-263
- **The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation** *RADIATION RESEARCH*
Ning, S. C., Laird, D., Cherrington, J. M., Knox, S. J.
2002; 157 (1): 45-51
- **Rotenone-induced G2/M cell cycle arrest and apoptosis in a human B lymphoma cell line PW** *BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS*
Armstrong, J. S., Hornung, B., Lecane, P., Jones, D. P., Knox, S. J.
2001; 289 (5): 973-978

- **Radioimmunotherapy of B-cell NHL.** *Current pharmaceutical biotechnology*
Meredith, R. F., Knox, S. J.
2001; 2 (4): 327-339
- **Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas** *JOURNAL OF CLINICAL ONCOLOGY*
Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J., Fehrenbacher, L., Lister, T. A., Stagg, R. J., Tidmarsh, G. F., KROLL, S., Wahl, R. L., Knox, S. J., Vose, et al
2001; 19 (19): 3918-3928
- **Bcl-2 inhibits apoptosis induced by mitochondrial uncoupling but does not prevent mitochondrial transmembrane depolarization** *EXPERIMENTAL CELL RESEARCH*
Armstrong, J. S., Steinauer, K. K., French, J., Killoran, P. L., Walleczek, J., Kochanski, J., Knox, S. J.
2001; 262 (2): 170-179
- **Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Murtha, A. D., Knox, S. J., Hoppe, R. T., Rupnow, B. A., Hanson, J.
2001; 49 (1): 3-15
- **Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Steinauer, K. K., Gibbs, I., Ning, S. C., French, J. N., Armstrong, J., Knox, S. J.
2000; 48 (2): 325-328
- **Bcl-2 overexpression results in enhanced capacitative calcium entry and resistance to SKF-96395-induced apoptosis** *CANCER RESEARCH*
Williams, S. S., French, J. N., Gilbert, M., Rangaswami, A. A., Walleczek, J., Knox, S. J.
2000; 60 (16): 4358-4361
- **Clinical radioimmunotherapy** *SEMINARS IN RADIATION ONCOLOGY*
Knox, S. J., Meredith, R. F.
2000; 10 (2): 73-93
- **Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas** *JOURNAL OF CLINICAL ONCOLOGY*
Vose, J. M., Wahl, R. L., Saleh, M., Rohatiner, A. Z., Knox, S. J., Radford, J. A., Zelenetz, A. D., Tidmarsh, G. F., Stagg, R. J., Kaminski, M. S.
2000; 18 (6): 1316-1323
- **Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer** *CLINICAL CANCER RESEARCH*
Knox, S. J., Goris, M. L., Tempero, M., Weiden, P. L., Gentner, L., Breitz, H., ADAMS, G. P., Axworthy, D., Gaffigan, S., Bryan, K., Fisher, D. R., Colcher, D., Horak, et al
2000; 6 (2): 406-414
- **Introduction** *Seminars in radiation oncology*
Knox, S. J.
2000; 10 (2): 71-72
- **Radiation absorbed dose estimation for Y-90-DOTA-biotin with pretargeted NR-LU-10/streptavidin** *CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS*
Breitz, H. B., Fisher, D. R., Goris, M. L., Knox, S., Ratliff, B., Murtha, A. D., Weiden, P. L.
1999; 14 (5): 381-395
- **G(2)/M-phase arrest and death by apoptosis of HL60 cells irradiated with exponentially decreasing low-dose-rate gamma radiation** *RADIATION RESEARCH*
Ning, S. C., Knox, S. J.
1999; 151 (6): 659-669
- **The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy** *APOPTOSIS*
Rupnow, B. A., Knox, S. J.
1999; 4 (2): 115-143

- **Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system** *RADIOTHERAPY AND ONCOLOGY*
Ning, S. C., Yu, N., Brown, D. M., Kanekal, S., Knox, S. J.
1999; 50 (2): 215-223
- **Myc activation reduces fibroblast clonogenicity via an apoptotic mechanism that can be suppressed by a soluble paracrine factor** *CANCER LETTERS*
Rupnow, B. A., Murtha, A. D., Chen, E., Knox, S. J.
1998; 127 (1-2): 211-219
- **Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy** *CANCER RESEARCH*
Rupnow, B. A., Murtha, A. D., Alarcon, R. M., Giaccia, A. J., Knox, S. J.
1998; 58 (9): 1779-1784
- **Pretargeted Radioimmunotherapy (TM) with antibody-streptavidin and Y-90 DOTA-Biotin (Avicidin (R)): Result of a dose escalation study.**
Breitz, H., Knox, S., Weiden, P., Goris, M., Murtha, A., Bryan, J., Axworthy, D., Seiler, C., Su, F. M., Beaumier, P., Reno, J.
SOC NUCLEAR MEDICINE INC.1998: 71P-71P
- **p53 mediates apoptosis induced by c-Myc activation in hypoxic or gamma irradiated fibroblasts** *CELL DEATH AND DIFFERENTIATION*
Rupnow, B. A., Alarcon, R. M., Giaccia, A. J., Knox, S. J.
1998; 5 (2): 141-147
- **Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Ning, S. C., Shui, C. X., Khan, W. B., Benson, W., Lacey, D. L., Knox, S. J.
1998; 40 (1): 177-187
- **Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts** *6th Conference on Radioimmunodetection and Radioimmunotherapy of Cancer*
Ning, S. C., Trisler, K., Wessels, B. W., Knox, S. J.
WILEY-BLACKWELL.1997: 2519-28
- **A prospective study of radiation therapy-associated thrombocytopenia** *BLOOD*
Knox, S. J., Varghese, A., Khan, W., Chen, E., MacManus, M., Ray, G., Lee, K., Lamborn, K. R.
1997; 90 (10): 4237-4238
- **Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor** *RADIATION RESEARCH*
Khan, W. B., Shui, C. X., Ning, S. C., Knox, S. J.
1997; 148 (3): 248-253
- **Influence of Bcl-2 overexpression on Na⁺/K⁺-ATPase pump activity: Correlation with radiation-induced programmed cell death** *JOURNAL OF CELLULAR PHYSIOLOGY*
Gilbert, M., Knox, S.
1997; 171 (3): 299-304
- **Radiotherapy-associated neutropenia and thrombocytopenia: Analysis of risk factors and development of a predictive model** *BLOOD*
MacManus, M., Lamborn, K., Khan, W., Varghese, A., Graef, L., Knox, S.
1997; 89 (7): 2303-2310
- **Modulation of c-myc activity and apoptosis in vivo** *CANCER RESEARCH*
Alarcon, R. M., Rupnow, B. A., Graeber, T. G., Knox, S. J., Giaccia, A. J.
1996; 56 (19): 4315-4319
- **Treatment of hormone-refractory prostate cancer with Y-90-CYT-356 monoclonal antibody** *CLINICAL CANCER RESEARCH*
Deb, N., Goris, M., Trisler, K., Fowler, S., Saal, J., Ning, S. C., Becker, M., Marquez, C., Knox, S.
1996; 2 (8): 1289-1297
- **Association of BCL-2 with membrane hyperpolarization and radioresistance** *JOURNAL OF CELLULAR PHYSIOLOGY*
Gilbert, M. S., Saad, A. H., Rupnow, B. A., Knox, S. J.
1996; 168 (1): 114-122
- **Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel** *RADIOTHERAPY AND ONCOLOGY*

- Ning, S., Trisler, K., Brown, D. M., Yu, N. Y., Kanekal, S., Lundsten, M. J., Knox, S. J.
1996; 39 (2): 179-189
- **Over-expression of Bcl-2 protects against apoptosis induced by the bioreductive cytotoxic drug SR4233 (tirapazamine)** *CELL DEATH AND DIFFERENTIATION*
Gilbert, M. S., Rupnow, B. A., Ramirez, D. A., Trisler, K. D., Knox, S. J.
1996; 3 (2): 215-222
 - **Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma** *CLINICAL CANCER RESEARCH*
Knox, S. J., Goris, M. L., Trisler, K., Negrin, R., Davis, T., Liles, T. M., GRILLOLOPEZ, A., Chinn, P., Varns, C., Ning, S. C., Fowler, S., Deb, N., Becker, et al
1996; 2 (3): 457-470
 - **Treatment of cutaneous T-Cell lymphoma with chimeric anti-CD4 monoclonal antibody** *BLOOD*
Knox, S., Hoppe, R. T., Maloney, D., Gibbs, I., Fowler, S., Marquez, C., Cornbleet, P. J., Levy, R.
1996; 87 (3): 893-899
 - **Overview of studies on experimental radioimmunotherapy.** *Cancer research*
Knox, S. J.
1995; 55 (23): 5832s-5836s
 - **(90)Yttrium labeled anti-CD20 therapy for recurrent B cell lymphoma**
Davis, T. A., Goris, M. L., Trisler, K. D., Negrin, R., Liles, T. M., Fowler, S. F., Deb, N., Becker, M., Marquez, C. M., Ning, S., Levy, R., Knox, S.
AMER SOC HEMATOLOGY.1995: 1080-80
 - **EFFECTS OF STEM-CELL FACTOR ON THE GROWTH AND RADIATION SURVIVAL OF TUMOR-CELLS** *CANCER RESEARCH*
Shui, C. X., Khan, W. B., Leigh, B. R., Turner, A. M., Wilder, R. B., Knox, S. J.
1995; 55 (15): 3431-3437
 - **MULTIPLE COURSES OF HIGH-DOSE TOTAL SKIN ELECTRON-BEAM THERAPY IN THE MANAGEMENT OF MYCOSIS-FUNGOIDES** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Becker, M., Hoppe, R. T., Knox, S. J.
1995; 32 (5): 1445-1449
 - **STEM-CELL FACTOR ENHANCES THE SURVIVAL OF MURINE INTESTINAL STEM-CELLS AFTER PHOTON IRRADIATION** *RADIATION RESEARCH*
Leigh, B. R., Khan, W., Hancock, S. L., Knox, S. J.
1995; 142 (1): 12-15
 - **Radioimmunotherapy of the Non-Hodgkin's Lymphomas.** *Seminars in radiation oncology*
Knox, S. J.
1995; 5 (4): 331-41
 - **STEM-CELL FACTOR ENHANCES THE SURVIVAL OF IRRADIATED HUMAN BONE-MARROW MAINTAINED IN SCID MICE** *STEM CELLS*
Leigh, B. R., Webb, S., Hancock, S. L., Knox, S. J.
1994; 12 (4): 430-435
 - **ORGAN MODELING IN THE QUANTITATION OF PLANAR IMAGES FOR DISTRIBUTION STUDIES** *9th Conference on Radioimmunodetection and Radioimmunotherapy of Cancer*
Goris, M. L., Knox, S. A., Nielsen, K. R., BOUILLANT, O.
JOHN WILEY & SONS INC.1994: 919-22
 - **EFFECT OF FILGRASTIM (G-CSF) IN HODGKINS-DISEASE PATIENTS TREATED WITH RADIATION** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Knox, S. J., Fowler, S., Marquez, C., Hoppe, R. T.
1994; 28 (2): 445-450
 - **THE HYPOXIC CYTOTOXIN SR-4233 INCREASES THE EFFECTIVENESS OF RADIOIMMUNOTHERAPY IN MICE WITH HUMAN NON-HODGKINS-LYMPHOMA XENOGRAFTS** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Wilder, R. B., McGann, J. K., SUTHERLAND, W. R., Waller, E. K., Minchinton, A. I., Goris, M. L., Knox, S. J.
1994; 28 (1): 119-126

- **DETERMINANTS OF LOW-DOSE RATE EFFECTS ASSOCIATED WITH RADIOIMMUNOTHERAPY** *ANTIBODY IMMUNOCONJUGATES AND RADIOPHARMACEUTICALS*
Knox, S. J., Sutherland, W., Goris, M. L.
1993; 6 (3): 197-207
- **THE EFFECT OF STEM-CELL FACTOR ON IRRADIATED HUMAN BONE-MARROW** *CANCER RESEARCH*
Leigh, B. R., Hancock, S. L., Knox, S. J.
1993; 53 (17): 3857-3859
- **CORRELATION OF TUMOR SENSITIVITY TO LOW-DOSE-RATE IRRADIATION WITH G2/M-PHASE BLOCK AND OTHER RADIOBIOLOGICAL PARAMETERS** *RADIATION RESEARCH*
Knox, S. J., Sutherland, W., Goris, M. L.
1993; 135 (1): 24-31
- **LOCAL HYPERTHERMIA AND SR-4233 ENHANCE THE ANTITUMOR EFFECTS OF RADIOIMMUNOTHERAPY IN NUDE-MICE WITH HUMAN COLONIC ADENOCARCINOMA XENOGRAFTS** *CANCER RESEARCH*
Wilder, R. B., Langmuir, V. K., Mendonca, H. L., Goris, M. L., Knox, S. J.
1993; 53 (13): 3022-3027
- **RADIOBIOLOGY OF RADIOLABELED ANTIBODY THERAPY AS APPLIED TO TUMOR DOSIMETRY** *MEDICAL PHYSICS*
Langmuir, V. K., Fowler, J. F., Knox, S. J., Wessels, B. W., SUTHERLAND, R. M., Wong, J. Y.
1993; 20 (2): 601-610
- **Determinants of low dose rate effects associated with radioimmunotherapy.** *Antibody Immunoconjugates and Radiopharmaceuticals*
Knox SJ, Sutherland W, Goris ML
1993; 6: 197-207
- **Response to letter by A. E. Amin regarding tumour size dependence of relative efficacy of radioimmunotherapy and external beam irradiation in tumour treatment.** *Radiotherapy Oncology*
Knox SJ, Goris ML, Wessels BW
1993; 25: 219-220
- **THE EFFECT OF UNLABELED MONOCLONAL-ANTIBODY (MAB) ON THE BIODISTRIBUTION OF I-131 ANTIIDIOTYPE MAB IN MURINE B-CELL LYMPHOMA** *RADIOTHERAPY AND ONCOLOGY*
Schiele, J., Knox, S. J., RUEHL, W., Goris, M. L.
1992; 24 (3): 169-176
- **OVERVIEW OF ANIMAL STUDIES COMPARING RADIOIMMUNOTHERAPY WITH DOSE EQUIVALENT EXTERNAL BEAM IRRADIATION** *RADIOTHERAPY AND ONCOLOGY*
Knox, S. J., Goris, M. L., Wessels, B. W.
1992; 23 (2): 111-117
- **THE BIODISTRIBUTION OF IN-111 ANTI-BFGF IN A VARIETY OF TUMORS - CORRELATION WITH CELL-BINDING ASSAYS** *ANNALS OF THE NEW YORK ACADEMY OF SCIENCES*
Knox, S. J., Brown, J. M., McGann, J., Sutherland, W., Goris, M. L., Herblin, W. F., Gross, J. L.
1991; 638: 497-502
- **RESULTS OF THE 1989 ASSOCIATION OF RESIDENTS IN RADIATION ONCOLOGY SURVEY** *31ST ANNUAL MEETING OF THE AMERICAN SOC OF THERAPEUTIC RADIOLOGY AND ONCOLOGY*
Corn, B. W., Taylor, B. W., Knox, S. J., Martz, K. L., Flynn, D. F.
PERGAMON-ELSEVIER SCIENCE LTD.1991: 1363-67
- **MYCOSIS-FUNGOIDES ARTHROPATHY** *ANNALS OF INTERNAL MEDICINE*
Berger, R. G., Knox, S. J., Levy, R., Sklar, J. L., Cohen, P., Reichert, T.
1991; 114 (7): 571-572
- **OBSERVATIONS ON THE EFFECT OF CHIMERIC ANTI-CD4 MONOCLONAL-ANTIBODY IN PATIENTS WITH MYCOSIS-FUNGOIDES** *BLOOD*
Knox, S. J., Levy, R., Hodgkinson, S., Bell, R., Brown, S., Wood, G. S., Hoppe, R., Abel, E. A., Steinman, L., Berger, R. G., Gaiser, C., Young, G., Bindl, et al
1991; 77 (1): 20-30

- **THE BIODISTRIBUTION OF IN-111 ANTI-BFGF IN A VARIETY OF TUMORS - CORRELATION WITH CELL-BINDING ASSAYS** *CONF ON THE FIBROBLAST GROWTH FACTOR FAMILY*
Knox, S. J., Brown, J. M., McGann, J., Sutherland, W., Goris, M. L., Herblin, W. F., Gross, J. L.
NEW YORK ACAD SCIENCES.1991: 497-502
- **DETERMINANTS OF THE ANTITUMOR EFFECT OF RADIOLABELED MONOCLONAL-ANTIBODIES** *CANCER RESEARCH*
Knox, S. J., Levy, R., MILLER, R. A., UHLAND, W., Schiele, J., RUEHL, W., FINSTON, R., DAYLOLLINI, P., Goris, M. L.
1990; 50 (16): 4935-4940
- **THE CHANGING FACE OF RADIATION ONCOLOGY** *SOUTHERN MEDICAL JOURNAL*
Meredith, R. F., Halberg, F. E., Knox, S. J.
1990; 83 (4): 488-488
- **HYPERTHERMIA AND RADIATION-THERAPY IN THE TREATMENT OF RECURRENT MERKEL CELL TUMORS** *CANCER*
Knox, S. J., Kapp, D. S.
1988; 62 (8): 1479-1486
- **2 INDEPENDENT PATHWAYS OF HELPER ACTIVITY PROVIDED BY A SINGLE T-CELL CLONE** *JOURNAL OF IMMUNOLOGY*
Shigeta, M., Takahara, S., Knox, S. J., Ishihara, T., Vitetta, E. S., Fathman, C. G.
1986; 136 (1): 34-38
- **EFFECT OF THYMOPOIETIN AND INTERLEUKIN-2 ON DEPRESSED MITOGENIC RESPONSIVENESS AND COLONY FORMATION OF LYMPHOCYTES FROM PATIENTS WITH PRELEUKEMIA** *THYMUS*
Knox, S. J., ROSENBLATT, L. S., Anderson, R. W., Greenberg, B. R.
1986; 8 (1-2): 33-44
- **RELATION OF AGE TO LYMPHOCYTE RADIOSENSITIVITY INVITRO** *HEALTH PHYSICS*
Knox, S. J., SHIFRINE, M., ROSENBLATT, L. S., Reeves, J. D., Woerner, S.
1984; 46 (2): 431-433
- **STUDIES OF LYMPHOCYTES-T IN PRELEUKEMIC DISORDERS AND ACUTE NONLYMPHOCYTIC LEUKEMIA - INVITRO RADIOSENSITIVITY, MITOGENIC RESPONSIVENESS, COLONY FORMATION, AND ENUMERATION OF LYMPHOCYTIC SUBPOPULATIONS** *BLOOD*
Knox, S. J., Greenberg, B. R., Anderson, R. W., ROSENBLATT, L. S.
1983; 61 (3): 449-455
- **LYMPHOCYTE ABNORMALITIES IN PRELEUKEMIA .1. DECREASED NK ACTIVITY, ANOMALOUS IMMUNOREGULATORY CELL SUBSETS AND DEFICIENT EBV RECEPTORS** *LEUKEMIA RESEARCH*
Anderson, R. W., Volsky, D. J., Greenberg, B., Knox, S. J., Bechtold, T., Kuszynski, C., Harada, S., Purtilo, D. T.
1983; 7 (3): 389-395
- **RADIATION-INDUCED INHIBITION OF HUMAN-LYMPHOCYTE BLASTOGENESIS - THE EFFECT OF SUPEROXIDE-DISMUTASE AND CATALASE** *INTERNATIONAL JOURNAL OF RADIATION BIOLOGY*
Knox, S. J., Misra, H. P., SHIFRINE, M., ROSENBLATT, L. S.
1982; 41 (3): 283-294
- **Growth of macrophage colonies from normal canine peripheral blood: morphological, cytochemical and functional parameters.** *Stem cells*
Knox, S. J., Wilson, F. D., Miller, C. H., ROSENBLATT, L. S., SHIFRINE, M.
1982; 1 (6): 325-344
- **ASSESSMENT OF THE INVITRO RADIOSENSITIVITY OF HUMAN PERIPHERAL-BLOOD LYMPHOCYTES** *RADIATION RESEARCH*
Knox, S. J., SHIFRINE, M., ROSENBLATT, L. S.
1982; 89 (3): 575-589
- **GROWTH OF HUMAN LYMPHOCYTE-T COLONIES FROM WHOLE-BLOOD - CULTURE REQUIREMENTS AND APPLICATIONS** *JOURNAL OF CELLULAR BIOCHEMISTRY*
Knox, S. J., Wilson, F. D., Greenberg, B. R., SHIFRINE, M.
1982; 18 (1): 15-24
- **CYTOGENETICS AND GRANULOPOIETIC EFFECTS OF BONE-MARROW FIBROBLASTIC CELLS IN FANCONIS ANEMIA** *BRITISH JOURNAL OF HAEMATOLOGY*

Greenberg, B. R., Wilson, F. D., Woo, L., Knox, S., Jenks, H., Taplett, J.
1981; 48 (1): 85-93

● **INCREASED RADIOSENSITIVITY OF A SUB-POPULATION OF LYMPHOCYTE-T PROGENITORS FROM PATIENTS WITH FANCONI ANEMIA** *BLOOD*

Knox, S. J., Wilson, F. D., Greenberg, B. R., SHIFRINE, M., ROSENBLATT, L. S., Reeves, J. D., Misra, H.
1981; 57 (6): 1043-1048

● **THE SELECTIVE GROWTH OF HUMAN LYMPHOCYTE-T COLONIES FROM WHOLE-BLOOD IN A SEMISOLID CULTURE SYSTEM** *EXPERIMENTAL HEMATOLOGY*

Knox, S. J., SHIFRINE, M., Wilson, F. D., ROSENBLATT, L. S.
1981; 9 (9): 926-937

● **A WHOLE-BLOOD TECHNIQUE FOR THE QUANTITATION OF CANINE LYMPHOCYTE-T PROGENITORS USING A SEMISOLID CULTURE SYSTEM** *EXPERIMENTAL HEMATOLOGY*

Wilson, F. D., Dyck, J. A., Knox, S. J., SHIFRINE, M.
1980; 8 (8): 1031-1039

● **Cell-mediated immunity in the dog in relation to disease: A review.** *Comp Immun Microbiol Infect Dis*

Knox SJ, Shifrine M
1980; 2: 405-415

● **Susceptibility of clinical isolates of *Pseudomonas aeruginosa* to antimicrobial agents.** *Pharmacol Ther*

Hirsh DC, Wiger N, Knox SJ
1979; 2: 275-278

● **PHARMACOKINETICS OF PENICILLIN-G IN TURKEY** *AMERICAN JOURNAL OF VETERINARY RESEARCH*

Hirsh, D. C., Knox, S. J., CONZELMAN, G. M., WIGER, N.
1978; 39 (7): 1219-1221